Adia Med Leads Charge to Standardize Umbilical Cord Stem Cell Use Nationwide, Prepares Presentation for New Head of DHHS and FDA
Adia Med (OTC Pink: ADIA) is spearheading an initiative to standardize umbilical cord stem cell use across the United States. The company plans to present pioneering standards to the Department of Health and Human Services and FDA, addressing widespread inconsistencies in stem cell therapies.
The initiative focuses on four key pillars:
- Homologous Use Standards to ensure stem cells are used according to natural functions
- Quality Control Protocols for harvesting, processing, and storage
- Mandatory Third-Party Verification of stem cell count and viability
- Best Practices Development through collaboration with experts
The company aims to combat the rising problem of substandard or non-viable stem cells being provided to patients. Under the proposed standards, every stem cell batch would require third-party verification certificates confirming quantity and viability, ensuring transparency and accountability in the industry.
Adia Med (OTC Pink: ADIA) sta guidando un'iniziativa per standardizzare l'uso delle cellule staminali del cordone ombelicale negli Stati Uniti. L'azienda prevede di presentare standard innovativi al Dipartimento della Salute e dei Servizi Umani e alla FDA, affrontando le diffuse incoerenze nelle terapie con cellule staminali.
L'iniziativa si concentra su quattro pilastri chiave:
- Standard di Uso Omologo per garantire che le cellule staminali siano utilizzate secondo le funzioni naturali
- Protocolli di Controllo Qualità per la raccolta, il trattamento e la conservazione
- Verifica Obbligatoria da Parte di Terzi del numero e della vitalità delle cellule staminali
- Sviluppo delle Migliori Pratiche attraverso la collaborazione con esperti
L'azienda mira a combattere il crescente problema delle cellule staminali di scarsa qualità o non vitali fornite ai pazienti. Sotto gli standard proposti, ogni lotto di cellule staminali richiederebbe certificati di verifica da parte di terzi che confermino quantità e vitalità, garantendo trasparenza e responsabilità nel settore.
Adia Med (OTC Pink: ADIA) está liderando una iniciativa para estandarizar el uso de células madre del cordón umbilical en los Estados Unidos. La empresa planea presentar estándares innovadores al Departamento de Salud y Servicios Humanos y a la FDA, abordando las inconsistencias generalizadas en las terapias con células madre.
La iniciativa se centra en cuatro pilares clave:
- Estándares de Uso Homólogo para garantizar que las células madre se utilicen de acuerdo con sus funciones naturales
- Protocolos de Control de Calidad para la recolección, procesamiento y almacenamiento
- Verificación Obligatoria de Terceros del conteo y viabilidad de las células madre
- Desarrollo de Mejores Prácticas a través de la colaboración con expertos
La empresa tiene como objetivo combatir el creciente problema de las células madre de baja calidad o no viables que se proporcionan a los pacientes. Bajo los estándares propuestos, cada lote de células madre requeriría certificados de verificación de terceros que confirmen la cantidad y viabilidad, garantizando transparencia y responsabilidad en la industria.
Adia Med (OTC Pink: ADIA)는 미국 전역에서 제대혈 줄기세포 사용을 표준화하기 위한 이니셔티브를 주도하고 있습니다. 이 회사는 보건복지부와 FDA에 혁신적인 기준을 제시할 계획이며, 줄기세포 치료의 광범위한 불일치를 해결하고자 합니다.
이 이니셔티브는 네 가지 주요 기둥에 중점을 두고 있습니다:
- 자연적 기능에 따라 줄기세포가 사용되도록 보장하는 동종 사용 기준
- 채취, 처리 및 저장을 위한 품질 관리 프로토콜
- 줄기세포 수와 생존 가능성에 대한 제3자 검증 의무
- 전문가와의 협력을 통한 모범 사례 개발
회사는 환자에게 제공되는 저품질 또는 비생존 가능 줄기세포 문제를 해결하고자 합니다. 제안된 기준에 따라, 모든 줄기세포 배치는 수량과 생존 가능성을 확인하는 제3자 검증 인증서를 요구하여 산업의 투명성과 책임을 보장합니다.
Adia Med (OTC Pink: ADIA) dirige une initiative visant à standardiser l'utilisation des cellules souches du cordon ombilical aux États-Unis. L'entreprise prévoit de présenter des normes novatrices au Département de la Santé et des Services sociaux ainsi qu'à la FDA, afin de remédier aux incohérences généralisées dans les thérapies par cellules souches.
L'initiative se concentre sur quatre piliers clés :
- Normes d'utilisation homologue pour garantir que les cellules souches sont utilisées selon leurs fonctions naturelles
- Protocoles de contrôle de qualité pour la collecte, le traitement et le stockage
- Vérification obligatoire par des tiers du nombre et de la viabilité des cellules souches
- Développement des meilleures pratiques grâce à la collaboration avec des experts
L'entreprise vise à lutter contre le problème croissant des cellules souches de mauvaise qualité ou non viables fournies aux patients. Selon les normes proposées, chaque lot de cellules souches nécessiterait des certificats de vérification par des tiers confirmant la quantité et la viabilité, garantissant ainsi la transparence et la responsabilité dans l'industrie.
Adia Med (OTC Pink: ADIA) leitet eine Initiative zur Standardisierung der Verwendung von Nabelschnur-Stammzellen in den Vereinigten Staaten. Das Unternehmen plant, bahnbrechende Standards dem Ministerium für Gesundheit und menschliche Dienste sowie der FDA vorzulegen, um weit verbreitete Inkonsistenzen in der Stammzelltherapie anzugehen.
Die Initiative konzentriert sich auf vier zentrale Säulen:
- Standards für homologe Verwendung, um sicherzustellen, dass Stammzellen gemäß ihren natürlichen Funktionen eingesetzt werden
- Qualitätskontrollprotokolle für Entnahme, Verarbeitung und Lagerung
- Verpflichtende Drittanbieter-Verifizierung der Stammzellanzahl und -lebensfähigkeit
- Entwicklung von Best Practices durch Zusammenarbeit mit Experten
Das Unternehmen zielt darauf ab, das wachsende Problem von minderwertigen oder nicht lebensfähigen Stammzellen zu bekämpfen, die Patienten bereitgestellt werden. Nach den vorgeschlagenen Standards müsste jede Stammzellcharge Drittanbieter-Verifizierungszertifikate vorlegen, die Menge und Lebensfähigkeit bestätigen und so Transparenz und Verantwortung in der Branche gewährleisten.
- Initiative positions company as industry leader in stem cell standardization
- Potential for regulatory partnership with DHHS and FDA
- Development of verifiable quality control standards could create competitive advantage
- Standards not yet approved by regulatory authorities
- Implementation timeline and costs unclear
- Success depends on voluntary industry adoption or regulatory mandate
Winter Park, Florida--(Newsfile Corp. - March 20, 2025) - Adia Med, a division of ADIA Nutrition Inc. (OTC Pink: ADIA), is driving a transformative effort to standardize umbilical cord stem cell use across the United States, prioritizing quality, safety, and accountability. This initiative sets rigorous best practices, mandates third-party verification, and ensures homologous applications, aiming to redefine excellence in regenerative medicine. Adia Med plans to present these pioneering standards to the new head of the Department of Health and Human Services, and the FDA, advocating for federal alignment to address widespread inconsistencies in stem cell therapies.
Cannot view this image? Visit:
https://images.newsfilecorp.com/files/10520/243473_fda.jpg
Patients nationwide have long grappled with a troubling issue: many clinics provide low-quality or non-viable—"dead"—stem cells, with no way for recipients to verify potency or quantity. This lack of oversight has eroded trust and limited the promise of regenerative medicine. Adia Med is stepping up to ensure every patient receives live, viable stem cells in the amounts promised, backed by unmatched quality controls.
"Umbilical cord stem cells could revolutionize healthcare, but only if patients can trust what they're getting," said Larry Powalisz, CEO of Adia Nutrition. "We're crafting a movement for reliability and excellence, and we're taking it to the new head of the Department of Health and Human Services and the FDA to create a national standard that protects patients and lifts the entire industry."
A Robust Standardization Framework
Adia Med's initiative rests on key pillars to fix current shortcomings:
Homologous Use Standards: Guidelines will ensure stem cells are used in line with their natural functions, boosting safety and effectiveness while curbing misuse risks.
Quality Control Protocols: Strict processes for harvesting, processing, and storing stem cells will maintain their therapeutic power, with standards covering donor screening, isolation, and banking.
Third-Party Verification: Every lab nationwide offering stem cell products would be required to provide third-party verification to guarantee a minimum stem cell count and viability for each batch, ensuring a consistent standard of quality, transparency, and reliability across the industry. This auditing ensures transparency and accountability.
Best Practices Development: Collaboration with stem cell experts, ethicists, and practitioners will produce adoptable standards to eliminate variability and enhance patient outcomes.
"Doctors should be getting their stem cells from a lab who has a third-party verified, FDA-validated process which guarantees quality, and we're pushing to make that the industry baseline with umbilical cord stem cells."
"Patients should never have to doubt the viability of their stem cells," said Dr. Sher, Chief Medical Officer of Stem Cells at Adia Med. "We're creating a standard where every patient receiving umbilical cord stem cells will receive a certificate from a third party, unequivocally verifying the quantity and viability of their specific batch." This hands-on assurance ensures doctors deliver stem cells from labs with independently verified, FDA-validated processes, setting a new benchmark for quality and boosting patient outcomes across the industry.
Tackling a Pressing Problem
Reports of patients receiving substandard or dead stem cells are rising, often unbeknownst to them. Adia Med's standards, backed by independent verification, will mandate live, viable cells in guaranteed minimum quantities, promising:
Patient Safety: Reduced risks from poor-quality cells or improper use.
Treatment Consistency: Reliable results nationwide, regardless of provider.
Industry Credibility: Ethical standards to eliminate bad actors and restore trust.
Federal Collaboration and Beyond
Adia Med aims to partner with the new head of the Department of Health and Human Services and the FDA, presenting these standards to shape a national framework. "With their leadership, we can end the uncertainty and deliver real benefits," Powalisz added. The company also invites input from regulators, medical professionals, and patient advocates, with participation details forthcoming at www.adiamed.com. Adia invites interested parties to reach out by filling out the contact form at www.adiamed.com.
For inquiries, questions, or further information, you can contact Larry Powalisz at ceo@adiamed.com or 321-788-0850.
About ADIA Nutrition Inc.:
Adia Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments.
Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.biolete.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/243473
FAQ
What standards is Adia Med (ADIA) proposing for umbilical cord stem cell use?
How will Adia Med's (ADIA) stem cell verification process work?
What problem is Adia Med (ADIA) addressing in the stem cell industry?
What regulatory approach is Adia Med (ADIA) taking for their stem cell standards?
